

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Brief Report

Survival of Inpatients under 5 Years Old with Bronchiolitis by Laboratory-Confirmed Respiratory Syncytial Virus Infection

Oliver Mendoza-Cano ¹, Xóchitl Trujillo ², Miguel Huerta ², Mónica Ríos-Silva ³, José Guzmán-Esquivel ^{4,5}, Verónica Benites-Godínez ^{6,7}, Jaime Alberto Bricio-Barrios ⁴, Eder Fernando Ríos-Bracamontes ⁸, Agustín Lugo-Radillo ^{9*} and Efrén Murillo-Zamora ^{4,5*}

- ¹ Facultad de Ingeniería Civil, Universidad de Colima, km. 9 carretera Colima-Coquimatlán, Coquimatlán, C.P. 28400, Colima, México. E-mail: oliver@ucol.mx
- ² Centro Universitario de Investigaciones Biomédicas, Universidad de Colima, Av. 25 de Julio 965, Col. Villas San Sebastián, C.P. 28045, Colima, Colima, México. E-mail: X.T., rosio@ucol.mx; M.H., huertam@ucol.mx
- ³ Universidad de Colima - CONACyT, Centro Universitario de Investigaciones Biomédicas, Av. 25 de Julio 965, Col. Villas San Sebastián, C.P. 28045, Colima, Colima, México. E-mail: mrios@ucol.mx
- ⁴ Facultad de Medicina, Universidad de Colima, Av. Universidad 333, Col. Las Víboras, C.P. 28040, Colima, Colima, México. E-mail: J.A.B.-B., jbricio@ucol.mx
- ⁵ Unidad de Investigación en Epidemiología Clínica, Instituto Mexicano del Seguro Social, Av. Lapislázuli 250, Col. El Haya, C.P. 28984 Villa de Álvarez, Colima, México. E-mail: J.G.-E., jose.esquivel@imss.gob.mx; E.M.-Z., efren.murilloza@imss.gob.mx
- ⁶ Coordinación de Educación en Salud, Instituto Mexicano del Seguro Social, Calzada del Ejército Nacional 14, Col. Fray Junípero Serra, C.P. 63160, Tepic, Nayarit, México. E-mail: veronica.benites@imss.gob.mx
- ⁷ Unidad Académica de Medicina, Universidad Autónoma de Nayarit, Ciudad de la Cultura Amado Nervo, C.P. 631555, Tepic, Nayarit, México
- ⁸ Departamento de Medicina Interna, Hospital General de Zona No. 1, Instituto Mexicano del Seguro Social, Av. Lapislázuli 250, Col. El Haya, C.P. 28984 Villa de Álvarez, Colima, México- E-mail: eder.rios@imss.gob.mx
- ⁹ Universidad Autónoma Benito Juárez de Oaxaca - CONACyT, Facultad de Medicina y Cirugía, Ex Hacienda Aguilera S/N Sur, C.P. 68020, Oaxaca, México. Email: alugora@conacyt.mx

* Correspondence: A.L.-R., +52 9515020700, alugora@conacyt.mx; E.M.-Z., +52 3123163795, efren.murilloza@imss.gob.mx

Abstract: Background: The respiratory syncytial virus infection (RSV) spread has been unusually high during 2022 and increasing trends have been documented. We aimed to assess the survival experience of children hospitalized due to bronchiolitis by laboratory-confirmed RSV. Methods: A nationwide and retrospective cohort was conducted in Mexico and data from 436 children aged 5 years and younger, with symptoms onset from August 2021 to November 2022, were analyzed. Survivor functions and 95% confidence intervals (CI) were computed by using the Kaplan-Meier method. Results: The survival rates were high, particularly within the first three weeks of admission. The 3-day survival was 99.8% (CI 95% 98.4-99.9%) and went to 98.9% (CI 95% 96.5-99.7%), 97.5% (CI 95% 91.9-99.3%), 86.7% (95% CI 48.2-97.2%), and 69.4% (95% CI 24.2-91.0%) on days 7, 14, 21 and 28 of hospital stay, respectively. We documented 5 fatal outcomes, and the mortality rate was 2.1 per 1,000 person-days. Conclusions: We analyzed a large set of pediatric patients with bronchiolitis by RSV and the presented results contribute to achieving a better understanding of the in-hospital evolution of this disease.

Keywords: Respiratory Syncytial Virus Infections; Child; Bronchiolitis; Survival

1. Introduction

The human respiratory syncytial virus (RSV) is a common and highly contagious pathogen in children and typically causes mild upper respiratory symptoms. In younger patients, the RSV infection may also cause bronchiolitis and, rarely, pneumonia [1]. Worldwide, this virus causes nearly 3.5 million hospitalizations and around 130 thousand deaths in children aged 5 years old or above [2].



The RSV spread has been unusually high during 2022 and increasing trends have been documented [3, 4], coinciding with the relaxation of non-pharmacological interventions to prevent the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In addition, published data regarding the clinical course of RSV pediatric inpatients are scarce. The aim of this study was to describe the survival experience of children (aged 5 years old and younger) inpatients with laboratory-positive infections by RSV.

2. Materials and Methods

We performed a retrospective and nationwide cohort study in Mexico from October 2022 to December 2022. Hospitalized children aged 5 years and older due to bronchiolitis (rhinorrhea, cough and any grade of respiratory distress), with laboratory-confirmed (reverse-transcription polymerase chain reaction test from nasopharyngeal swabs) RSV infection and symptoms onset from August 2021 to November 2022, were eligible. A broader description of the analytical procedures employed for the surveillance of respiratory viral pathogens was previously published [5].

Eligible children were identified from the nominal records of a normative system for the epidemiological surveillance of respiratory viral diseases that belongs to the Mexican Institute of Social Security [6]. Medical records and death certificates, when applicable, are the primary sources of the audited surveillance system.

We used the Kaplan-Meier method to compute survivor functions and 95% confidence intervals (CI) at different cut-offs. In hospital death was the failure variable and children with hospital discharge due to clinical improvement, as well as those that were still hospitalized on November 31, 2022, were censored.

3. Results

Data from 436 children were analyzed. Most of the enrolled patients were male (56.4%) the overall median age was 6 months and ranged (interquartile range) from 0 to 2 years. As observed in Figure 1, most of the cases occurred during the autumn and winter seasons.




Figure 1. Date of symptoms onset of the analyzed children with laboratory-confirmed respiratory syncytial virus infection, Mexico 2021 - 2022.

The total follow-up was 2,337 person-days and 5 deaths were registered. Therefore, the mortality rate in the study sample was 2.1 per 1,000 person-days. Three of the fatal

outcomes occurred within the first 96 hours of hospital admission and the remaining deaths took place on day 9 and 20, respectively. All the deaths occurred in children < 2 years old, and three of them were under the age of 6 months.

The survival functions (Figure 2) were 99.8% (CI 95% 98.4-99.9%), 98.9% (CI 95% 96.5-99.7%), 97.5% (CI 95% 91.9-99.3%), 86.7% (95% CI 48.2-97.2%), and 69.4% (95% CI 24.2-91.0%) at day 3, 7, 14, 21 and 28 from hospital admission, respectively.




Figure 2. Survivor functions of children inpatients with respiratory syncytial virus infection, Mexico 2021 - 2022.

4. Discussion

Our study characterized the survival experience of a large set of hospitalized children with laboratory-confirmed RSV infection. The presented results suggest that the first four days of hospital admission were particularly important when evaluating the survival probabilities in the study population since 60% of fatal outcomes occurred within this time framework. To the best of our knowledge, there are no published studies evaluating the survival experience of children inpatients with RSV infection.

The mortality in our study was significantly higher than the mortality observed in a population with similar characteristics from Singapore (11.5 vs. 1.9 per 1,000 children; $p = 0.003$) [7]. We also found that younger children, particularly those aged 0-6 months, were at higher risk of dying due to RSV infection, as previously described [8].

The potential limitations of the study must be cited. First, we lacked of genomic data regarding the specific RSV strain identified in each of the analyzed cases. Published data documented that RSV A/GA5 infections are at increased risk for severe symptoms [9]. Second, the number of deaths was (fortunately) low ($n = 5$), and we were unable to identify factors predicting the survival of children inpatients through a Cox regression model. The analyzed surveillance system collects relevant information, such as patients' age and comorbid conditions, which impact on survival rates and that would have enriched our analysis [10].

5. Conclusions

We analyzed a large set of pediatric patients with bronchiolitis by RSV and the presented results contribute to achieving a better understanding of the in-hospital evolution of this disease. The first four days of hospital stay seem to be relevant for the survival probabilities of these patients and opportune and accurate medical management must be ensured to reduce the related disease burden.

Author Contributions: Conceptualization, A.L.-R., O.M.-C., and E.M.-Z.; methodology, X.T., M.H., A.L.-R., and E.F.R.-B.; software, J.G.-E., and V.B.-G.; validation, M.R.-S., X.T., M.H., and J.A.B.-B.; formal analysis, J.G.-E., and O.M.-C.; investigation, V.B.-G.; resources, V.B.-G.; data curation, E.M.-Z.; writing—original draft preparation, M.R.-S., O.M.-C., E.M.-Z., J.A.B.-B., and E.F.R.-B.; writing—review and editing, X.T., M.H., J.G.-E., V.B.-G., and A.L.-R. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: This study was evaluated and approved by the Local Health Research Committee (601) of the Mexican Institute of Social Security (approval R-2020-601-022).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data that support the findings of this study are not openly available and are available from the corresponding author upon reasonable request.

Acknowledgments: We would like to thank the Mexican Institute of Social Security for its valuable support in carrying out this research.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Jain H, Schweitzer JW, Justice NA. Respiratory Syncytial Virus Infection. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2022.
2. Di Mattia G, Nenna R, Mancino E, Rizzo V, Pierangeli A, Villani A, et al. During the COVID-19 pandemic where has respiratory syncytial virus gone? *Pediatr Pulmonol*. 2021. <https://doi.org/10.1002/ppul.25582>.
3. Krilov LR, Roberts NJ Jr. Respiratory Syncytial Virus (RSV) Update. *Viruses*. 2022;14(10):2110. <https://doi.org/10.3390/v14102110>.
4. Qiu W, Zheng C, Huang S, Zhang Y, Chen Z. Epidemiological Trend of RSV Infection Before and During COVID-19 Pandemic: A Three-Year Consecutive Study in China. *Infect Drug Resist*. 2022;15:6829-6837. <https://doi.org/10.2147/IDR.S388231>.
5. Fernandes-Matano L, Monroy-Muñoz IE, Bermúdez de León M, Leal-Herrera YA, Palomec-Nava ID, Ruiz-Pacheco JA, et al. Analysis of influenza data generated by four epidemiological surveillance laboratories in Mexico, 2010-2016. *Epidemiol Infect*. 2019;147:e183. <https://doi.org/10.1017/S0950268819000694>.
6. General Directorate of Epidemiology of Mexico. Standardized Guidelines for Epidemiological and Laboratory Surveillance of viral respiratory disease (updated on April 8, 2022) [cited 2022 December 9]. Available from: https://www.gob.mx/cms/uploads/attachment/file/715444/Lineamiento_VE_y_Lab_Enf_Viral_05042022.pdf (accessed on December 9, 2022)
7. Lee MW, Goh AE. Mortality in children hospitalised with respiratory syncytial virus infection in Singapore. *Singapore Med J*. 2021;62(12):642-646. <https://doi.org/10.11622/smedj.2020075>.
8. Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. *Lancet*. 2022;399(10340):2047-2064. [https://doi.org/10.1016/S0140-6736\(22\)00478-0](https://doi.org/10.1016/S0140-6736(22)00478-0).
9. Rodriguez-Fernandez R, Tapia LI, Yang CF, Torres JP, Chavez-Bueno S, Garcia C, et al. Respiratory Syncytial Virus Genotypes, Host Immune Profiles, and Disease Severity in Young Children Hospitalized With Bronchiolitis. *J Infect Dis*. 2017;217(1):24-34. <https://doi.org/10.1093/infdis/jix543>.
10. Löwensteyn YN, Willemsen JE, Mazur NI, Scheltema NM, van Haastregt NCJ, Buuren AAAT, et al. Nosocomial RSV-related In-hospital Mortality in Children <5 Years: A Global Case Series. *Pediatr Infect Dis J*. 2023;42(1):1-7. <https://doi.org/10.1097/INF.0000000000003747>.